EPCORE DLBCL-4 randomized transplant-ineligible and/or CAR T–ineligible R/R LBCL patients to epcoritamab-lenalidomide versus R-GemOx after ≥1 prior systemic line including anti-CD20 therapy. Primary ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...

This multicenter retrospective cohort study included 516 patients age ≥14 years diagnosed with DLBCL between January 2016 and December 2023 at two tertiary hospitals in Saudi Arabia. Data on ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling often in the ...

If these drugs are designed to target cancer, why don't they work?Treatments that harness the power of the immune system to ...

Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) ...

Approved CD20×CD3 bispecifics (epcoritamab, glofitamab, mosunetuzumab) deliver meaningful ORR/CR in heavily pretreated DLBCL, but PFS remains modest, motivating combination strategies.